Search results
Results from the WOW.Com Content Network
Spondyloarthritis (SpA), also known as spondyloarthropathy, is a collection of clinical syndromes that are connected by genetic predisposition and clinical manifestations. [1] The best-known clinical subtypes are enteropathic arthritis (EA), psoriatic arthritis (PsA), ankylosing spondylitis (AS), and reactive arthritis (ReA). [ 2 ]
Axial spondyloarthritis (also often referred to as axSpA) is a chronic, immune-mediated disease predominantly affecting the axial skeleton (sacroiliac joints and spine). [1] The term itself is an umbrella term characterizing a diverse disease family united by shared clinical and genetic features, such as the involvement of the axial skeleton. [ 2 ]
About one third of those with ankylosing spondylitis have severe disease, which reduces life expectancy. [52] As increased mortality in ankylosing spondylitis is related to disease severity, factors negatively affecting outcomes include: [50] [53] Male sex [54] Plus three of the following in the first two years of disease:
My mental health was at a low from this drastic life change and being in pain 24/7. I dealt with anxiety and depression while waiting for real answers, and it didn’t help that I isolated myself ...
As a seronegative spondyloarthropathy, laboratory analysis of blood will show that the patient is rheumatoid factor negative and often HLA-B27 positive. [7] The most common triggers are intestinal infections (with Salmonella , Shigella or Campylobacter ) and sexually transmitted infections (with Chlamydia trachomatis ); [ 8 ] however, it also ...
Americans are living longer than they did in 1965, when Medicare was established. Back then, average U.S. life expectancy was about 70; today it’s about 77 and a half—down slightly from a pre ...
For premium support please call: 800-290-4726 more ways to reach us
The BASDAI or Bath Ankylosing Spondylitis Disease Activity Index is a validated diagnostic test which allows a physician, usually a rheumatologist, to determine the effectiveness of a current drug therapy, or the need to institute a new drug therapy for the treatment of Ankylosing spondylitis (AS).